Family medicine is an important setting for managing cardiovascular risk factors and preventing the onset of heart disease, as well as managing risk factors following a cardiac event. If a patient is a smoker, explained Dr. Andrew Pipe, Chief of Prevention and Rehabilitation at the University of...
Search
Displaying 21 - 40 of 224
Following Burgon’s talk at the International Forum, Philip Devereaux of McMaster University spoke about Canada’s unique place in the world of cardiovascular medicine. Not only is cardiovascular disease (CVD) the leading cause of death globally but by 2020, the incidence in developing countries is...
The CARDIoGRAM consortium, of which the Heart Institute is a founding member, reported finding 13 new genetic regions associated with increased risk for coronary artery disease and heart attack. CARDIoGRAM brings together research teams from around the world to pool data sets and increase their...
Dr. Ruth McPherson, an active CARDIoGRAM participant and a co-author on the interferon biomarker study, was honoured by the AHA Council on Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) with its Special Recognition Award. Dr. McPherson, a tireless clinician and scientist, directs the...
Mutations in the gene are associated with striated muscle diseases such as cardiomyopathy and muscular dystrophy. Filling in the unknowns about a previously unexplored gene is a good way to get the attention of your peers. Heart Institute scientist Patrick Burgon is doing just that with a gene he...
The State of the Science Lecture on Women and Heart Disease by Anne Rosenfeld of the Oregon Health Sciences University made it clear that there is much to learn about the ways the disease is unique to women. What we do know indicates that risk, symptoms, progression and treatment of CVD are all...
Successfully managing heart failure is one the looming issues for cardiovascular medicine, with prevalence expected to grow significantly over the coming decades. The plenary session “Engineering Success in Heart Failure” looked at where things are headed, from therapy to devices to delivery of care...
Once again, the University of Ottawa Heart Institute had more than 40 clinical and research presentations on the program at the annual American Heart Association Scientific Sessions. These, along with other major developments in the world of cardiovascular medicine, made for a lively conference. New...
Several Heart Institute staffers offered their expertise in invited talks touching on a broad range of topics. Scientist Erik Suuronen, PhD, uses tissue engineering techniques to develop methods for regenerating damaged heart muscle. In his presentation, called “The Matrix: Stem Cell Delivery...
Some of the biggest news to come out of AHA this year was the results from preliminary clinical trials of two new LDL cholesterol-lowering drugs that show a substantial decrease in LDL levels well below the reductions seen with statins or ezetimibe alone. The new drugs belong to a class called PCSK9...
The use of stem cells for regenerating damaged heart tissue offers great potential, but many technical questions remain. Understanding which cell types are most beneficial and how they should be employed is a central issue. Several clinical trials involving stem cells were presented at AHA. Two were...
Research from around the world was presented at the 2014 American Heart Association (AHA) Scientific Sessions in November. The following highlights range from large drug trials to new information about the causes and of heart disease and the value of good heart health. Preventing Clots Following...
More than 32,000 Canadians go into cardiac arrest each year outside of a hospital and more than 90 per cent of them die. In many cases, this is because bystanders didn’t have adequate knowledge of CPR or access to an automated external defibrillator (AED). Guidelines and studies presented at the...
Although most cases of high blood pressure have no easily identifiable cause, the condition’s effects are clear, including increased risk of stroke, heart attack, and heart failure. The medical consensus is that using medications to lower blood pressure benefits patients, but how low has remained an...
Over the last decade, much has been learned about the genetic risk factors for cardiovascular disease. In the long run, as researchers uncover how variations in these genes lead to heart disease, this knowledge may lead to new preventive drugs and treatments. But in the meantime, doctors have been...
At this year’s premier international gathering for heart disease, the American Heart Association Scientific Sessions, sharing expertise was a major aspect of the University of Ottawa Heart Institute’s presence. In Ask the Expert and seminar sessions, surgeons Marc Ruel, Munir Boodhwani, David...
Each of us breathes in 10,000 or more litres of air every day, so it’s no surprise that the quality of that air can impact our health. Whether in large urban centres or more rural settings, air pollution can be a fact of life. As it turns out, these airborne pollutants—ground-level ozone, nitrogen...
The American Heart Association Scientific Sessions is the largest conference for cardiovascular science and medicine in the world. The staff of the University of Ottawa Heart Institute is once again responsible for many expert clinical talks and research presentations. This guide highlights those...
The American Heart Association Scientific Sessions is the largest conference for cardiovascular science and medicine in the world. The staff of the University of Ottawa Heart Institute is once again responsible for many expert clinical talks and research presentations. This guide highlights those...
The world’s largest cardiovascular conference, the American Heart Association Scientific Sessions, convenes in New Orleans on November 12. The Ottawa Heart Institute has 45 program items on the agenda covering a wide range of science and clinical practice. Find it all with our program guide. 2016...